PHASE-III RANDOMIZED COMPARISON OF POSTOPERATIVE ADJUVANT CHEMOTHERAPY WITH 2-YEAR ORAL UFT (URACIL TEGAFUR) VERSUS 6-CYCLE CMF (CYCLOPHOSPHAMIDE/METHOTREXATE/5-FLUOROURACIL) IN HIGH-RISK NODE-NEGATIVE BREAST-CANCER PATIENTS/

Authors
WATANABE T
Citation
T. Watanabe, PHASE-III RANDOMIZED COMPARISON OF POSTOPERATIVE ADJUVANT CHEMOTHERAPY WITH 2-YEAR ORAL UFT (URACIL TEGAFUR) VERSUS 6-CYCLE CMF (CYCLOPHOSPHAMIDE/METHOTREXATE/5-FLUOROURACIL) IN HIGH-RISK NODE-NEGATIVE BREAST-CANCER PATIENTS/, Japanese Journal of Clinical Oncology, 28(1), 1998, pp. 77-80
Citations number
8
Categorie Soggetti
Oncology
Journal title
Japanese Journal of Clinical Oncology → ACNP
ISSN journal
03682811
Volume
28
Issue
1
Year of publication
1998
Pages
77 - 80
Database
ISI
SICI code
0368-2811(1998)28:1<77:PRCOPA>2.0.ZU;2-P